Open AccessAutomated small‐scale protein purification and analysis for accelerated development of protein therapeutics
Author(s) -
LeSaout Xavier,
Costioli Matteo,
Jordan Lynn,
Lambert Jeremy,
Beighley Ross,
Provencher Laurel,
Gerwe Brian,
McGuire Kevin,
Verlinden Nico,
Barry Andrew
Publication year - 2016
Publication title -
engineering in life sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.547
H-Index - 57
eISSN - 1618-2863
pISSN - 1618-0240
DOI - 10.1002/elsc.201400252
Subject(s) - fast protein liquid chromatography , pipette , miniaturization , chromatography , microscale chemistry , size exclusion chromatography , chemistry , scale (ratio) , scale up , materials science , nanotechnology , high performance liquid chromatography , mathematics , biochemistry , mathematics education , physics , quantum mechanics , classical mechanics , enzyme
Small‐scale protein purification presents opportunities for accelerated process development of biotherapeutic molecules. Miniaturization of purification conditions reduces time and allows for parallel processing of samples, thus offering increased statistical significance and greater breadth of variables. The ability of the miniaturized platform to be predictive of larger scale purification schemes is of critical importance. The PerkinElmer JANUS BioTx Pro and Pro‐Plus workstations were developed as intuitive, flexible, and automated devices capable of performing parallel small‐scale analytical protein purification. Preprogrammed methods automate a variety of commercially available ion exchange and affinity chromatography solutions, including miniaturized chromatography columns, resin‐packed pipette tips, and resin‐filled microtiter vacuum filtration plates. Here, we present a comparison of microscale chromatography versus standard fast protein LC (FPLC) methods for process optimization. In this study, we evaluated the capabilities of the JANUS BioTx Pro‐Plus robotic platform for miniaturized chromatographic purification of proteins with the GE ӒKTA Express system. We were able to demonstrate predictive analysis similar to that of larger scale purification platforms, while offering advantages in speed and number of samples processed. This approach is predictive of scale‐up conditions, resulting in shorter biotherapeutic development cycles and less consumed material than traditional FPLC methods, thus reducing time‐to‐market from discovery to manufacturing.